Skip to main content

Research Repository

Advanced Search

A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: the comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYp

Mukhtar, Omar; Cheriyan, Joseph; Cockcroft, John R.; Collier, David; Coulson, James M.; Dasgupta, Indranil; Faconti, Luca; Glover, Mark; Heagerty, Anthony M.; Khong, Teck K.; Lip, Gregory Y.H.; Mander, Adrian P.; Marchong, Mellone N.; Martin, Una; McDonnell, Barry J.; McEniery, Carmel M.; Padmanabhan, Sandosh; Saxena, Manish; Sever, Peter J.; Shiel, Julian I.; Wych, Julie; Chowienczyk, Phil J.; Wilkinson, Ian B.

Authors

Omar Mukhtar

Joseph Cheriyan

John R. Cockcroft

David Collier

James M. Coulson

Indranil Dasgupta

Luca Faconti

MARK GLOVER Mark.Glover@nottingham.ac.uk
Clinical Associate Professor

Anthony M. Heagerty

Teck K. Khong

Gregory Y.H. Lip

Adrian P. Mander

Mellone N. Marchong

Una Martin

Barry J. McDonnell

Carmel M. McEniery

Sandosh Padmanabhan

Manish Saxena

Peter J. Sever

Julian I. Shiel

Julie Wych

Phil J. Chowienczyk

Ian B. Wilkinson



Abstract

BACKGROUND: Ethnicity, along with a variety of genetic and environmental factors, is thought to influence the efficacy of antihypertensive therapies. Current UK guidelines use a "black versus white" approach; in doing so, they ignore the United Kingdom's largest ethnic minority: Asians from South Asia.
STUDY DESIGN: The primary purpose of the AIM-HY INFORM trial is to identify potential differences in response to antihypertensive drugs used as mono- or dual therapy on the basis of self-defined ethnicity. A multicenter, prospective, open-label, randomized study with 2 parallel, independent trial arms (mono- and dual therapy), AIM-HY INFORM plans to enroll a total of 1,320 patients from across the United Kingdom. Those receiving monotherapy (n = 660) will enter a 3-treatment (amlodipine 10 mg od; lisinopril 20 mg od; chlorthalidone 25 mg od), 3-period crossover, lasting 24 weeks, whereas those receiving dual therapy (n = 660) will enter a 4-treatment (amlodipine 5 mg od and lisinopril 20 mg od; amlodipine 5 mg od and chlorthalidone 25 mg od; lisinopril 20 mg od and chlorthalidone 25 mg od; amiloride 10 mg od and chlorthalidone 25 mg od), 4-period crossover, lasting 32 weeks. Equal numbers of 3 ethnic groups (white, black/black British, and Asian/Asian British) will ultimately be recruited to each of the trial arms (ie, 220 participants per ethnic group per arm). Seated, automated, unattended, office, systolic blood pressure measured 8 weeks after each treatment period begins will serve as the primary outcome measure.
CONCLUSION: AIM-HY INFORM is a prospective, open-label, randomized trial which aims to evaluate first- and second-line antihypertensive therapies for multiethnic populations.

Journal Article Type Article
Publication Date Oct 1, 2018
Journal American Heart Journal
Print ISSN 0002-8703
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 204
Pages 102-108
APA6 Citation Mukhtar, O., Cheriyan, J., Cockcroft, J. R., Collier, D., Coulson, J. M., Dasgupta, I., …Wilkinson, I. B. (2018). A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: the comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial. American Heart Journal, 204, 102-108. https://doi.org/10.1016/j.ahj.2018.05.006
DOI https://doi.org/10.1016/j.ahj.2018.05.006
Keywords Cardiology and Cardiovascular Medicine
Publisher URL https://www.sciencedirect.com/science/article/pii/S000287031830156X?via%3Dihub

Files



You might also like



Downloadable Citations

;